1. 1 Brandsch, M. (2009) Transport of drugs by proton-coupled transporters: pearls and pitfalls. Expert Opin. Drug Metab. Toxicol. 5; 887–905.
2. 2 Christopher, R., Convingtone, P., Davenport, M., Fleck, P., Mekki, Q. A., Wann, E. R., et al. (2008) Pharmacokinetics, pharmacodynamics, and tolerability of single increasing does of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin. Ther. 30; 513–527.
3. 3 Clancy, B. and Cauller, L. J. (1998) Reduction of background autofluorescence in brain sections following immersion in sodium borohydride. J. Neurosci. Methods 83; 97–102.
4. 4 Drucker, D. J. and Nauck, N. A. (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368; 1696–1705.
5. 5 Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., et al. (2014) Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N. Engl. J. Med. 370; 794–797.